Medicines Use Reviews: Frequently asked questions

Medicines Use Reviews: Frequently asked questions

July 29, 2019

The PSNC Services Team has received a number of queries relating to the Medicines Use Review (MUR) service under the new CPCF settlement.

The most common queries received have been highlighted below:

 Q. Can I provide 250 MURs in the first half of 2019/20?
No. A maximum of 200 MURs only can be provided in the first half of 2019/20 (1st April 2019 – 30th September 2019) as stated in Part VIC in the Drug Tariff. Any additional MURs (contractors can provide a maximum of 250 MURs in 2019/20) can be conducted in the second half of 2019/2020, i.e. from 1st October 2019 onwards.

Q. I have only provided 100 MURs in the first half of 2019/20. Can I still provide MURs in the second half of 2019/20?
Yes. Carrying out 200 MURs in the first half of 2019/20 is not a pre-requisite requirement for providing further MURs in the second half. Contractors can still provide 250 MURs across 2019/20 (with a maximum of 200 MURs in the first half of 2019/20).

Q. If I only provide 100 MURs in the first half of 2019/20, does this mean I can only provide 50 MURs in the second half of 2019/20 or can I provide 150?
If a contractor only provides 100 MURs in the first half of 2019/20, they can provide an additional 150 MURs in the second half of 2019/20.

Q. How many MURs can I provide in 2020/21?
A total of 100 MURs can be provided in 2020/21.

Q. Will the target groups for MURs be changing?
Further guidance on MUR target groups will be provided shortly as discussions on this are still ongoing. Any changes to the target groups will take effect from 1st October 2019.

Q. When will the MUR service be decommissioned?
The MUR service will be decommissioned at the end of the 2020/21 financial year.



Posted in: ,


More Latest News >

Metformin Safety Update

The Medicines and Healthcare products Regulatory Agency (MHRA) has been made aware that outside of the UK very low amounts...

PQS: NSAID quality criterion

This news story highlights several points on the non-steroidal anti-inflammatory drug (NSAID) quality criterion of the Pharmacy Quality Scheme (PQS)...